24/7 Wall Street
16 Aug 2026, 19:45 UTC · 5h ago
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
16 Aug 2026, 19:45 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Baupost Group completely liquidated its entire stake in Vaxcyte (PCVX) during the June quarter. — The total exit by a high-profile value investor like Seth Klarman signals a loss of conviction in a clinical-stage company with no revenue.
-0.60Vaxcyte reported a Q2 2026 net loss of $284.30 million and conducted a $601.80 million equity raise in February 2026. — High cash burn and reliance on equity offerings create shareholder dilution risk, which may justify institutional exits.
-0.40Baupost Group completely exited its position in Willis Towers Watson (WTW). — While WTW is profitable and growing, the total exit suggests an opportunistic trade rather than a long-term conviction hold.
-0.30Continue reading
6 related stories
Search tags
Vaxcyte's primary value catalyst, the OPUS-1 Phase 3 readout, is not expected until Q4 2026. — This establishes a long-dated binary event that creates high volatility and requires high conviction to hold.
+0.10Which stocks this story touches
Major institutional investor Baupost dumped its entire stake amid high losses and dilution concerns.
Mentioned as a sponsor offering an attractive incentive for new investment users.
Baupost exited its entire position, though the company's individual financial performance remains positive.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
5h ago
